US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

13.49

-0.0300-0.22%

Post-market: 13.490.00000.00%19:53 EST

Volume:540.91K

Turnover:7.26M

Market Cap:422.10M

PE:-6.40

High:13.73

Open:13.50

Low:13.14

Close:13.52

52wk High:50.40

52wk Low:11.48

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.70

T/O Rate:3.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1087

EPS(LYR):-2.3387

ROE:-28.78%

ROA:-19.52%

PB:2.18

PE(LYR):-5.77

Loading ...

Overview Company News Filings

Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating

ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald

Neural Therapeutics Moves to Take Full Control of German CBD Retailer Hanf.com

Protara Therapeutics to Participate in Upcoming Investor Conferences

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia

Intensity Therapeutics Inc trading halted, news pending

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity

Enlivex Therapeutics management to meet virtually with BTIG

Unnatural Products in Pact With Novartis to Develop Macrocyclic Peptide Therapeutics

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Aprea Therapeutics announces additional clinical activity for APR-1051

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Acrivon Therapeutics announces completion, certification of CLIA certified lab

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":13.49,"timestamp":1772226000000,"preClose":13.52,"halted":0,"volume":540909,"hourTrading":{"tag":"盘后","latestPrice":13.49,"preClose":13.49,"latestTime":"19:53 EST","volume":99213,"amount":1338366.7596,"timestamp":1772240000613,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0022189349112425563,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"Market Closed","change":-0.03,"latestTime":"02-27 16:00:00 EST","open":13.5,"high":13.73,"low":13.14,"amount":7263659.251944,"amplitude":0.043639,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":13.52,"postHourTrading":{"tag":"盘后","latestPrice":13.49,"preClose":13.49,"latestTime":"19:53 EST","volume":99213,"amount":1338366.7596,"timestamp":1772240000613,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6979926191889101,"impliedVol":0.9544,"impliedVolPercentile":0.6592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-19.52%","roe":"-28.78%","lyrEps":-2.338654,"volumeRatio":0.6979926191889101,"shares":31289969,"dividePrice":0,"high":13.73,"amplitude":0.043639,"preClose":13.52,"low":13.14,"week52Low":11.48,"pbRate":"2.18","psRate":"24.12","week52High":50.4,"institutionHeld":0,"latestPrice":13.49,"eps":-2.10871,"divideRate":0,"volume":540909,"delay":0,"ttmEps":-2.10871,"open":13.5,"prevYearClose":16,"prevWeekClose":11.59,"prevMonthClose":15.82,"prevQuarterClose":16,"fiveDayClose":11.59,"twentyDayClose":17.78,"sixtyDayClose":30.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742706000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-02-27","current":-6.397276,"percent":0.855292,"low":-26.69966,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"high":-5.069183,"avg":-12.746789,"sd":5.133348,"marketCap":423040380},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380}],"updateTime":1772319083077},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612329284","title":"Aprea Therapeutics: Emerging Dose-Responsive Efficacy and Favorable Safety of APR-1051 Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2612329284","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612329284?lang=en_us&edition=fundamental","pubTime":"2026-02-20 01:15","pubTimestamp":1771521321,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Aprea Therapeutics. The associated price target remains the same wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aprea-therapeutics-emerging-dose-responsive-efficacy-and-favorable-safety-of-apr-1051-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aprea-therapeutics-emerging-dose-responsive-efficacy-and-favorable-safety-of-apr-1051-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2612828952","title":"ProQR Therapeutics participates in a conf call hosted by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2612828952","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612828952?lang=en_us&edition=fundamental","pubTime":"2026-02-19 23:50","pubTimestamp":1771516254,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Biotech Analyst Seedhouse holds a conference call with CEO de Boer and CMO Lopez on February 23 at 9 am. Published first on TheFl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-participates-in-a-conf-call-hosted-by-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-participates-in-a-conf-call-hosted-by-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4585","BK4539","BK4007","LABU","BK4588"],"gpt_icon":0},{"id":"2612286398","title":"Neural Therapeutics Moves to Take Full Control of German CBD Retailer Hanf.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2612286398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612286398?lang=en_us&edition=fundamental","pubTime":"2026-02-19 23:07","pubTimestamp":1771513677,"startTime":"0","endTime":"0","summary":"An update from Neural Therapeutics Inc. ( ($TSE:NURL) ) is now available. Neural Therapeutics has applied to the Canadian Securities Exchange for a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neural-therapeutics-moves-to-take-full-control-of-german-cbd-retailer-hanf-com?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neural-therapeutics-moves-to-take-full-control-of-german-cbd-retailer-hanf-com?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MSOS","LENZ","BK4139","BK4539","ACB","CBD","BK4557","BK4007","BK4113"],"gpt_icon":0},{"id":"2612833222","title":"Protara Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612833222","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612833222?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:00","pubTimestamp":1771506000,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb.  19, 2026  (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, toda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/19/3241013/0/en/Protara-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2612440735","title":"BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2612440735","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612440735?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:00","pubTimestamp":1771502400,"startTime":"0","endTime":"0","summary":"Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia Large patient population affected by Alzhei","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/19/3240957/0/en/BioXcel-Therapeutics-to-Host-Virtual-Roundtable-Featuring-Leading-Medical-Experts-Addressing-Latest-Developments-in-Treatment-of-Acute-Agitation-in-Alzheimer-s-Dementia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KOL","LENZ","BK4007","BK4181","BK4585","BK4539","HST","BK4218","ESG","BK4588"],"gpt_icon":0},{"id":"2612473567","title":"Intensity Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2612473567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612473567?lang=en_us&edition=fundamental","pubTime":"2026-02-19 08:50","pubTimestamp":1771462217,"startTime":"0","endTime":"0","summary":"19:50 EST Intensity Therapeutics (INTS) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","INTS","BK4139","BK4539"],"gpt_icon":0},{"id":"2612942905","title":"Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612942905","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612942905?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:05","pubTimestamp":1771448700,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Feb.  18, 2026  (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240608/0/en/Avalo-Therapeutics-Announces-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2612429071","title":"Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612429071","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612429071?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:01","pubTimestamp":1771448460,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., Feb.  18, 2026  (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240601/0/en/Keros-Therapeutics-Announces-Participation-at-Upcoming-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","XBI","BK4539","BK4139","XLV","BK4585","LABU","BK4581","LENZ","LU0128526141.USD","BK4137","BK4588","HCSG","BK4007"],"gpt_icon":0},{"id":"2612425828","title":"Aquestive Therapeutics: Strengthened Leadership and Regulatory Clarity Underpin Buy Rating on Anaphylm Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2612425828","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612425828?lang=en_us&edition=fundamental","pubTime":"2026-02-19 03:35","pubTimestamp":1771443330,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Aquestive Therapeutics today and set a price target of $9.00. Francois Briseb...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aquestive-therapeutics-strengthened-leadership-and-regulatory-clarity-underpin-buy-rating-on-anaphylm-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aquestive-therapeutics-strengthened-leadership-and-regulatory-clarity-underpin-buy-rating-on-anaphylm-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2612428500","title":"Enlivex Therapeutics management to meet virtually with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2612428500","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612428500?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:40","pubTimestamp":1771436432,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on February 23-26 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-management-to-meet-virtually-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enlivex-therapeutics-management-to-meet-virtually-with-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2612442610","title":"Unnatural Products in Pact With Novartis to Develop Macrocyclic Peptide Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2612442610","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612442610?lang=en_us&edition=fundamental","pubTime":"2026-02-18 23:47","pubTimestamp":1771429620,"startTime":"0","endTime":"0","summary":"Unnatural Products unveiled a deal with Novartis worth up to $1.8 billion to develop macrocyclic peptide therapeutics.The biotechnology company developing macrocyclic peptides to address previously undruggable targets said Wednesday that it had entered a research collaboration and licensing agreement with Novartis for an undisclosed program.The collaboration joins Unnatural Products's AI-enhanced macrocycle discovery engine and Novartis' development and commercialization capabilities to create therapeutics with potential applications for cardiovascular disease, the company said.Under the agreement, Unnatural Products will receive up to $100 million in upfront and pre-investigational new drug milestone payments. In addition, the company may receive up to $1.7 billion in development, regulatory and commercial milestones.Novartis will take responsibility for IND-enabling studies and all subsequent clinical development, manufacturing and global commercialization of products emerging from t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4588","LU0320765489.SGD","BK4578","IE00B4R5TH58.HKD","BK4139","NVS","IE00B2B36J28.USD","BK4007","IE00BFTCPJ56.SGD","BK4532","LU0208291251.USD","LENZ","IE0002141913.USD","IE0009355771.USD","LU0211331839.USD","BK4585","LU0070302665.USD","BK4539"],"gpt_icon":0},{"id":"2612244158","title":"Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612244158","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612244158?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:05","pubTimestamp":1771423500,"startTime":"0","endTime":"0","summary":"In-person presentation on Wednesday, February 25th at 11:00 AM PT TAMPA, Fla. and LONDON, Feb.  18, 2026  (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240315/0/en/Akari-Therapeutics-to-Present-at-the-2026-Biocom-Global-Partnering-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4539","LENZ"],"gpt_icon":0},{"id":"2612463964","title":"Aprea Therapeutics announces additional clinical activity for APR-1051","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463964","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612463964?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:17","pubTimestamp":1771420633,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics (APRE) announced additional preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-additional-clinical-activity-for-apr-1051-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-announces-additional-clinical-activity-for-apr-1051-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APRE","LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2612463244","title":"Theriva Biologics licenses SYN-020 to Rasayana Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463244","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612463244?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:16","pubTimestamp":1771420604,"startTime":"0","endTime":"0","summary":"Theriva Biologics (TOVX) reported the out-licensing of SYN-020, to Rasayana Therapeutics, a privately-held company targeting the Gut-Organ axis bio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/theriva-biologics-licenses-syn-020-to-rasayana-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/theriva-biologics-licenses-syn-020-to-rasayana-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","TOVX","BK4007"],"gpt_icon":0},{"id":"2612446649","title":"Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446649","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446649?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:15","pubTimestamp":1771420500,"startTime":"0","endTime":"0","summary":"Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240189/0/en/Allarity-Therapeutics-Doses-First-Patients-in-VA-Funded-Phase-2-Trial-Focused-on-Small-Cell-Lung-Cancer-with-High-Unmet-Need.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ALLR","BK4539","LENZ"],"gpt_icon":0},{"id":"2612446379","title":"Acrivon Therapeutics announces completion, certification of CLIA certified lab","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446379?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:11","pubTimestamp":1771420264,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics (ACRV) announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acrivon-therapeutics-announces-completion-certification-of-clia-certified-lab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acrivon-therapeutics-announces-completion-certification-of-clia-certified-lab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ACRV","BK4139","BK4539","BK4007","CLIA"],"gpt_icon":0},{"id":"2612628446","title":"Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2612628446","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612628446?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419600,"startTime":"0","endTime":"0","summary":"Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse eventsRepresents second patient with PR to harbor PPP2R1A mutati","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240156/0/en/Aprea-Therapeutics-Announces-Additional-Positive-Clinical-Activity-for-WEE1-Inhibitor-APR-1051-Including-Second-Partial-Response-in-Ongoing-ACESOT-1051-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2612446939","title":"Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446939","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446939?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419600,"startTime":"0","endTime":"0","summary":"- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales -","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240133/0/en/Theriva-Biologics-Licenses-SYN-020-to-Rasayana-Therapeutics-for-Multiple-Indications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2612446927","title":"Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446927","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446927?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb.  18, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redef","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240150/0/en/Spyre-Therapeutics-Announces-Presentations-at-the-21st-ECCO-Congress-Supporting-Differentiated-Profile-of-SPY003-and-Novel-Animal-Studies-Demonstrating-Superiority-of-Combination-A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2612446901","title":"Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446901","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446901?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419600,"startTime":"0","endTime":"0","summary":"Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240164/0/en/Acrivon-Therapeutics-Strengthens-its-Precision-Medicine-Therapeutics-Capabilities-with-Launch-of-Internal-CLIA-Certified-Laboratory.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CLIA","BK4539","BK4139","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}